Chalermrat BunchorntavakulTawesak TanwandeeRangsit UniversityMahidol University2018-11-232018-11-232015-12-01Gastroenterology Clinics of North America. Vol.44, No.4 (2015), 883-90015581942088985532-s2.0-84947616929https://repository.li.mahidol.ac.th/handle/20.500.14594/36234© 2015 Elsevier Inc. The management of hepatitis C virus (HCV) infection in special populations is challenging. The efficacy and safety data of the currently approved all-oral direct-acting antiviral combinations, including sofosbuvir, ledipasvir, daclatasvir, paritaprevir/ritonavir/ombitasvir plus dasabuvir (3D), and ribavirin, is compelling for use in special HCV populations, as has recently been recommended by expert guidelines. The treatment regimens and sustained virological response rates for special populations are nearly similar to those of the general HCV population. Sofosbuvir is not recommended in patients with severe renal impairment, and simeprevir and 3D regimen are not recommended for those with decompensated liver disease.Mahidol UniversityMedicineReviewSCOPUS10.1016/j.gtc.2015.06.002